Tendering process for pneumococcal conjugate vaccine

This page is a knowledge crystal of subtype assessment. The page identifier is Op_en6352
Moderator:Nobody (see all) Click here to sign up.
Upload data {{#opasnet_base_link:Op_en6352}}

Question

• How should vaccine products be compared in the national procurement of the pneumococcal conjugate vaccine.

Scope

• We restrict the analysis to vaccination within the infant immunisation programme.
• We specify criteria for comparing pneumococcal conjugate vaccine products (in Finnish: vertailuperusteet).
• The aim is to prepare selection criteria that lead to choice of the economically most advantageous tender.
• We discuss assumptions underlying the epidemiological model and the cost-effectiveness analysis.
• The analysis is based on current knowledge of the efficacy and impact of pneumococcal conjugate vaccines.
• The procurement can only involve a product that has trading license in Finland (see Lääkelain 20a§).
• The procurement needs to obey the Act on public procurement (julkisista hankinnoista annetun lain mukainen).
• The discussion on these pages does not bind the preparation of the procurement.

Rationale

The rationale has been summarised in the following 3 pages (currently in Finnish): Vertailuperusteet, Epidemiologinen_mallinnus ja Taloudellinen arviointi.

Rokotteiden vertailu perustuu hintaan ja hyötyyn (ks. vertailuperusteet). Epidemiologinen hyöty tarkoittaa arvioitua vakavien pneumokokkitapausten vähenemää, jos rokote otettaisiin kansalliseen rokotusohjelmaan. Arvio tehdään epidemiologisen mallin avulla. Rokotusohjelman vaikuttavuus määrätään epidemiologisen mallin antaman arvion perusteella terveyteen liittyvänä elämänlaadun muutoksena. Kustannusvaikuttavin rokotevalmiste valitaan taloudellisen arvioinnin menetelmin.